U.S. Markets close in 52 mins

Dyadic Reports Continued Positive Business Trends and Scientific Results in Fourth Quarter 2019

  • Expanded ZAPI Program and Positive Preliminary Results from ZAPI Animal Study
  • New Collaboration Agreement with Top Ten Pharmaceutical Company
  • Expanded Research Relationship with Leading Pharmaceutical Company
  • IIBR Collaboration Achieved Expression of Fc-fusion Enzyme to Counter Biological Attacks
  • Glycoengineering Data Reinforces Company's Accelerated Glyco Strategy
  • Two New Patent Applications

JUPITER, FL / ACCESSWIRE / January 6, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today provided an update on its recent business developments and scientific results in the fourth quarter of 2019.

Expansion of ZAPI Program

In December, the Company received positive preliminary results from the ZAPI animal studies and expanded its research collaboration with ZAPI to express two additional proteins. Preliminary results from the animal studies indicated that Dyadic's C1 antigen demonstrated very strong performance in protecting both cattle and mice from the Schmallenberg virus (SBV). As a result, ZAPI expanded the scope of Dyadic's involvement in the program and Dyadic expects to receive additional funding from the ZAPI consortium in support of production of the two additional targets.

"We are very pleased with the initial promising results from this study and expect the final results to be published during the second quarter of 2020," said Mr. Mark Emalfarb, CEO of Dyadic. "We are also excited to be working on two additional proteins for the animal health market where we already have ongoing collaborations with two of the top four animal health companies."

New Research Collaboration with Top Tier Pharma

The Company entered into a new collaboration with a top ten pharmaceutical company in Q4. This is the sixth proof of concept research collaboration that the Company has announced in 2019 including the Serum Institute of India.

Research License with An Existing Collaborator

In the second quarter of 2019, Dyadic announced a research collaboration with the microbial fermentation group of a leading pharmaceutical company to evaluate C1 for their own internal use. The nonexclusive research license is with an affiliate of the original corporate client, a top 25 pharmaceutical company. The nonexclusive license allows for our collaborator to perform certain experiments and manipulations to the C1 cell lines to create potential licensed products, and for any other internal noncommercial purpose determined by our collaborator to be necessary to evaluate the C1 technology. The collaborator will invest its own resources to evaluate C1 technology for their customers globally.

"This is another exciting endorsement of the potential of our C1 technology. Our ongoing fully funded research collaboration with this collaborator helped us to obtain a research license with another part of the global organization where we will tech transfer our C1 technology to their in-house lab for their scientists to further evaluate it, possibly improving upon it, with the objective of broadening and accelerating the adoption and use of C1 globally.

Mr. Emalfarb continued, "We are very excited to announce these two new programs with industry leading companies. Our expanding business portfolio further highlights the significant runway for value creation at Dyadic, given the broad-based application potential of our proprietary C1 gene expression technology, targeted approach to business development and diverse types of collaborations with top tier animal and human pharmaceutical and biotech companies."

Dyadic and IIBR Collaboration to Combat Chemical and Biological Threats

In our collaboration with the Israeli Institute of Biological Research (IIBR), a proprietary IIBR Fc-fusion enzyme has been expressed using our C1 technology. This Acetyl Choline Esterase enzyme has previously been shown to provide certain countermeasures against nerve agents such as sarin and VX gas which are toxic and rapidly acting chemical warfare agents. The recombinant IIBR Fc-fusion enzyme, produced in HEK293 cells, has been shown to provide longer lasting protection than the common Acetyl Choline Esterase.

"This collaboration with IIBR demonstrates a new class of proteins that can be expressed from C1 to produce larger amounts of lower cost countermeasures for chemical and biological threats globally. We look forward to continuing our research collaboration with the IIBR and the expansion of our C1 technology for other government agencies to help with their national security and defense needs," added Mr. Emalfarb.

Glyco-engineering Program Updates

In late November, Dyadic announced that it had demonstrated that its C1 strain had been successfully glycoengineered to impart the core human like G0 glycan structure at G0 glycosylation levels of up to 95%, exceeding the Company's initial objective of 90%. This scientific data was presented at the Protein and Antibody Engineering Summit (PEGS Europe) and is a key milestone in the Company's ongoing C1 research and development program related to expressing glycosylated proteins such as monoclonal antibodies (mAbs), Fc-fusion and other glycoproteins. The Company believes that these results support Dyadic's decision to advance this program to continue to develop C1 cell lines that have the potential to impart additional complex human glycoforms, such as G0F, G2 and G2F. One of our goals is to be able to demonstrate that the C1 technology can make glycoproteins at large volumes and lower cost, with similar or better performance to glycosylated proteins expressed from Chinese Hamster Ovary Cells (CHO cells).

"We believe that the recent results from our glycoengineering program demonstrate the potential applicability of our C1 technology for developing and manufacturing certain biosimilars, biobetters and new biomolecules which is why we have decided to accelerate this company-funded program. These results support our belief that Dyadic, in collaboration with its partners, will be able to develop and manufacture biopharmaceuticals for certain diseases such as cancer, and rheumatoid arthritis in large volumes at lower cost, making these drugs accessible to a much broader population," stated Mr. Emalfarb.

Patent Applications

In the fourth quarter of 2019, the Company filed two additional patent applications in the areas of metabolites and glycoengineering.

JP Morgan Conference in January 2020

Dyadic management will be in San Francisco and available for meetings during the week of JP Morgan Annual Healthcare Conference. Dyadic management will be presenting at the following conferences:

BFC Global Healthcare Investment Conference
Sunday, January 12, 2020
Invited Speaker Panel: 9:15-10:15 a.m. Pacific Time
Investor presentation: 2:30 p.m. Pacific Time
The St. Regis San Francisco
Mark Emalfarb

China Focus
Sunday, January 12, 2020
Presentation time: 10:50 a.m. Pacific Time
Grand Hyatt San Francisco
Ping Rawson

Biotech Showcase
Monday, January 13, 2020
Presentation time: 10:00 a.m. Pacific Time
Hilton San Francisco Union Square
Mark Emalfarb/Matthew Jones

Potential business partners and investors can contact mjones@dyadic.com to set up a meeting.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Additionally, and more recently, Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV), certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic's website at http://www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website at http://www.dyadic.com

Contact:

Dyadic International, Inc.
Mark Emalfarb, CEO
Phone: +1 (561) 743-8333
Email: memalfarb@dyadic.com

SOURCE: Dyadic International, Inc.



View source version on accesswire.com:
https://www.accesswire.com/572122/Dyadic-Reports-Continued-Positive-Business-Trends-and-Scientific-Results-in-Fourth-Quarter-2019

  • Business
    Barrons.com

    Boeing Stock Is Halted, Pending News

    Trading in stock in commercial aerospace giant (BA) has been halted pending news, but before the suspension, shares had fallen almost $18, or 5.5%, to $306.22. Both accidents have been linked to flight-control software, and Boeing has been working for months on fixes, as well as training and hardware improvements to make the plane safer. Aviation stakeholders believe the Federal Aviation Administration can complete a review of the fixes Boeing has submitted to it during the first quarter of 2020.

  • Guggenheim Says Market a ‘Ponzi Scheme’ That Must Collapse
    Business
    Bloomberg

    Guggenheim Says Market a ‘Ponzi Scheme’ That Must Collapse

    Scott Minerd has a message for his fellows at Davos who are applauding rallying markets: Things aren't as good as they seem. The Guggenheim Partners investment chief likened the inflation of asset prices caused by the loose money policies of central banks to a “ponzi scheme” that eventually must collapse. “We will reach a tipping point when investors will awake to the rising tide of defaults and downgrades,” he wrote in a letter from the World Economic Forum meeting.

  • How To Invest $100,000 (and Turn It Into $1 Million)
    Business
    SmartAsset

    How To Invest $100,000 (and Turn It Into $1 Million)

    As you invest for retirement, becoming a millionaire might be a reasonable goal. Yes, millionaire status is no longer rarefied air, and depending on your income needs, having at least $1 million in the bank might be necessary to last you through retirement. If you're interested in reaching millionaire status as an investor, here's what you need to know to pull it off.

  • `Substantial' Market Correction Is Unlikely, Fidelity's Richards Says
    Business
    Bloomberg

    `Substantial' Market Correction Is Unlikely, Fidelity's Richards Says

    Anne Richards, chief executive officer of Fidelity International, discusses the outlook for the global economy, financial markets and active management in 2020. She speaks with Francine Lacqua on "Bloomberg Markets" at the World Economic Forum's annual meeting in Davos, Switzerland.

  • Dow Leads Market Indexes Lower Amid Reports Of First U.S. Coronavirus Case
    Business
    Investor's Business Daily

    Dow Leads Market Indexes Lower Amid Reports Of First U.S. Coronavirus Case

    Key market indexes headed south in midday trade, led by the Dow Jones Industrial Average, after CNN reported the CDC is set to announce the first U.S. case of the China coronavirus. The Nasdaq, down nearly 0.2%, reversed back into the red, the S&P 500 was also down 0.2% and the Dow Jones industrials fell more than 2% in the stock market today. Small caps tracked by the Russell 2000 were sharply lower, down 0.8%.

  • Stock Market Sells Off As China Virus Scare Hits U.S.; These 4 Big Name Stocks Shoot Higher
    Business
    Investor's Business Daily

    Stock Market Sells Off As China Virus Scare Hits U.S.; These 4 Big Name Stocks Shoot Higher

    Chinese online retailing giant and IBD 50 name Alibaba fell 2.5%, but remains extended from a cup-with-handle base above an 88.38 buy point. The Dow took a second big hit after CNBC reported that sources at Boeing revealed the jet-making giant doesn't expect regulators to clear its troubled 737 Max until June or July. Boeing fell 5.5% to its lowest level in a year and remains below its 200-day and 50-day moving average lines.

  • Founder of world’s largest hedge fund says ‘cash is trash’ as the Dow soars to records
    Business
    MarketWatch

    Founder of world’s largest hedge fund says ‘cash is trash’ as the Dow soars to records

    If there are investors who believe cash is king amid this market bull run, they ought to think again, suggests Ray Dalio. The billionaire founder of the hedge fund Bridgewater Associates said during a CNBC interview on Tuesday on the sidelines of the World Economic Forum in Davos, Switzerland, that investors should be buying this market, rather than seeking safety in cash. “Cash is trash,” said the hedge-fund luminary, who founded Westport, Conn.–based Bridgewater in 1975.

  • How to Invest $10 Million for Income
    Business
    SmartAsset

    How to Invest $10 Million for Income

    A $10 million nest egg can last you decades, especially if you make smart investments that prioritize income generation. Wealthy investors should consider mutual funds that have high minimum investment requirements, in part because they tend to have lower fees. Plus, mutual funds help investors generate income from earned dividends on stocks and interest on bonds in the portfolio.

  • 9 Signs You Are Not Financially OK to Retire
    Business
    Investopedia

    9 Signs You Are Not Financially OK to Retire

    What it really takes to retire is a solid grasp of your budget, a carefully considered investment and spending plan for your life savings, debt that's under control, and a plan you're excited about for how you'll spend your days. With that in mind, here are 10 signs you might not be ready to retire yet. Struggling to Pay Current Bills It goes without saying that if you're struggling to pay your bills with a paycheck from work, retiring won't make things easier.

  • Legendary investor Paul Tudor Jones says market today is like early ’99, driven by ‘insane monetary policy’
    Business
    MarketWatch

    Legendary investor Paul Tudor Jones says market today is like early ’99, driven by ‘insane monetary policy’

    Billionaire investor Paul Tudor Jones is nothing short of flabbergasted by economic and monetary policy coming from Washington. We're just in the craziest monetary-fiscal [policy] mix in history. It's so explosive, it defies imagination.

  • How Are Dividends on IRAs Taxed?
    Business
    Investopedia

    How Are Dividends on IRAs Taxed?

    Dividend-earning stocks and mutual funds can help your retirement portfolio grow more quickly, as long as you reinvest the dividends. In a regular investment account, the dividends and capital gains you earn benefit from capital gains tax treatment. For example, if you are in the 10% or 15% tax bracket, you would pay 0% taxes on dividends and long-term capital gains.

  • Boeing Stock Dives As 737 Max Return Slips Further; Rival Airbus Jet Gains
    Business
    Investor's Business Daily

    Boeing Stock Dives As 737 Max Return Slips Further; Rival Airbus Jet Gains

    Boeing stock tumbled after the company confirmed it now sees getting regulator clearance for the 737 Max's return well into the summer. The aerospace giant sees regulators signing off on the Boeing 737 Max in June or July, sources told CNBC, months later than what it previously expected. "We are informing our customers and suppliers that we are currently estimating that the ungrounding of the 737 MAX will begin during mid-2020," Boeing said in a statement later.

  • Is It Time to Buy These 3 Beaten-Down Stocks? Analysts Say Yes
    Business
    TipRanks

    Is It Time to Buy These 3 Beaten-Down Stocks? Analysts Say Yes

    The term 'buy when there's blood in the streets' was coined in the 18th century by Baron Rothchild. While some investors automatically avoid underperforming names, the ones willing to take the risk can often receive handsome reward once the company at question executes a turnaround. With this in mind, We'll open up the TipRanks database and take a look at three beaten down stock which those in the know think are ripe for a trend reversal.

  • 11 self-made millionaires reveal the best advice they ever got
    Business
    USA TODAY

    11 self-made millionaires reveal the best advice they ever got

    The best (and worst) advice I ever received came in the form of an insult from my long-term boyfriend and business partner. 4. “All events in your life are neutral until you label them.” During my recovery from a near-death cycling accident, I struggled with many “life isn't fair” moments.

  • Gurus Back Micron Amidst the Revival of the Semiconductor Industry
    Business
    GuruFocus.com

    Gurus Back Micron Amidst the Revival of the Semiconductor Industry

    The semiconductor industry is cyclical, and picking companies to invest in can turn out to be a tricky task. The uncertainty surrounding the sector often leads to the mispricing of securities, which provides great investment opportunities. For example, I published an article on Skyworks Solutions (SWKS) on Sept. 20, 2019, when shares were trading at around $81, in which I assigned a target price of $109.

  • UBS misses targets, dials back ambitions
    Business
    Reuters Videos

    UBS misses targets, dials back ambitions

    Famous for wealth management, UBS suffered in Q4 as wealthy clients took $4.7 billion of their money elsewhere. Tuesday's (January 21) update from the Swiss bank also shows that despite a near 130% rise in quarterly net profit it missed profit and cost targets for 2019, prompting it to dial back on some financial goals. Like others, UBS is hurting badly from the low-to-no interest rate environment.

  • These 10 Rules Made Warren Buffett a Billionaire
    Business
    MoneyWise

    These 10 Rules Made Warren Buffett a Billionaire

    Warren Buffett may be worth tens of billions, but he still lives simply, and his strategies for smart investing and amassing wealth aren't too complicated either. Buffett's first key to prosperity has little to do with picking stocks. "Without good communication skills, you won't be able to convince people to follow you even though you see over the mountain and they don't," Buffett once told a Stanford MBA student.

  • Tesla stock rally ‘extremely unusual,’ analyst says
    Business
    MarketWatch

    Tesla stock rally ‘extremely unusual,’ analyst says

    Tesla Inc. stock skyrocketed Tuesday as one analyst said the shares' ongoing rally is “extremely unusual” in the automobile and industrial sectors. Tesla shares (TSLA) rose more than 6% and traded as high as $545.90, on track for a record close. Tesla stock has doubled in six months and gained 190% since its trough in June “baffling many investors,” said Bernstein analyst Toni Sacconaghi in a note Tuesday.

  • Artificial Intelligence Stocks To Buy And Watch Amid Rising AI Competition
    Business
    Investor's Business Daily

    Artificial Intelligence Stocks To Buy And Watch Amid Rising AI Competition

    Instead, look for companies using AI technology to improve products or gain a strategic edge. Chipmaker Intel, for example, on Dec. 16 acquired Israel-based Habana Labs for $2 billion. Intel in 2016 bought Nervana Systems in an earlier move to take on AI chip leader Nvidia.

  • The Next $1 Trillion Stock After Microsoft, Apple, Alphabet Is ...
    Business
    Investor's Business Daily

    The Next $1 Trillion Stock After Microsoft, Apple, Alphabet Is ...

    And analysts think the company's shares will hit 2,177.96 a share in 12 months, says S&P Global Market Intelligence. If Amazon hits that target the company would be worth $1.1 trillion. Amazon would be the fourth S&P 500 stock to be worth $1 trillion, after Google parent Alphabet did it last week.

  • Why This Top-Notch Biotech Stock Just Plunged By Double Digits
    Business
    Investor's Business Daily

    Why This Top-Notch Biotech Stock Just Plunged By Double Digits

    Further, Big Pharma rivals are likely to launch cardiovascular and lipid drugs with massive sales forces before Arrowhead reaches the market, he said. "We see the next 12 months as far more challenging than the past two years as Arrowhead faces sky-high expectations in the face of increasingly clear competitive headwinds," he said in a note to clients. Foroohar initiated coverage with an ARWR stock price target of 32.

  • Using Your 401(k) to Pay Off a Mortgage
    Business
    Investopedia

    Using Your 401(k) to Pay Off a Mortgage

    Those reduced expenses may mean that the 401(k) distribution used to pay off the mortgage needn't necessarily be replenished prior to leaving the workforce. Consequently, the benefit of the mortgage payoff persists, leaving the individual or couple with a smaller need to draw income from investment or retirement assets throughout retirement years. The excess cash from not having a mortgage payment may also prove beneficial for unexpected expenses that could arise during retirement, such as medical or long-term care costs not covered by insurance.

  • Alexander Hamilton dispensed of Trump’s impeachment defense in 1788
    Politics
    Quartz

    Alexander Hamilton dispensed of Trump’s impeachment defense in 1788

    US founding father Alexander Hamilton would probably counsel president Donald Trump to come up with a better defense than the one offered by Trump's attorneys ahead of his looming Senate impeachment trial. Trump's primary argument—issued in a response to the House impeachment trial brief and summons he received this weekend—is that the impeachment is bunk because the articles fail to allege a “violation of law or crime, let alone 'high crimes and misdemeanors' as required by the Constitution.” The president also complains that he's been deprived of due process, relying on the standards outlined for criminal trials. The historical record, however, doesn't support Trump's position that the two processes must mirror each other in form or function.

  • Five Things for Tuesday, including Intel layoff reports
    Business
    American City Business Journals

    Five Things for Tuesday, including Intel layoff reports

    Intel's Data Center Group could make job cuts of 25 to 33 percent, according to tech websites as well as the Oregonian. An Intel spokesperson would not comment on the reports to the Portland Business Journal on Friday, but noted that the company will hold its fourth-quarter conference call Thursday. A drive through the Portland area could cost more than just the aggravation of stop-and-go traffic.

  • Billionaire Salesforce founder: 'Capitalism as we know it is dead'
    Business
    Yahoo Finance UK

    Billionaire Salesforce founder: 'Capitalism as we know it is dead'

    This obsession that we have with maximising profits for shareholders alone has led to incredible inequality and a planetary emergency. Benioff, who is worth $7.7bn (£6bn) according to Forbes, made the comments during a panel on 'Stakeholder Capitalism' — the idea that companies should work to maximise the value for all 'stakeholders' such as employees and society, rather than just maximising shareholder value. Stakeholder capitalism is finally hitting a tipping point,” Benioff said.